{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:44:01Z","timestamp":1791909841714,"version":"4.3.4"},"reference-count":57,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,4,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Adult T-cell leukemia\/lymphoma (ATL) is an aggressive T-cell lymphoproliferative malignancy caused by human T-cell leukemia virus type 1 (HTLV-1). ATL is an orphan disease with no curative drug treatment regimens urgently needing new combination therapy. HTLV-1-infected cells rely on viral proteins, Tax and HBZ (HTLV-1-b-ZIP factor), to activate the transcription of various host genes that are critical for promoting leukemic transformation. Inhibition of bromodomain and extraterminal motif (BET) protein was previously shown to collapse the transcriptional network directed by BATF3 super-enhancer and thereby induced ATL cell apoptosis. In the current work, by using xenograft, ex vivo, and in\u00a0vitro models, we demonstrated that I-BET762 (BETi) synergized with copanlisib (PI3Ki) and bardoxolone methyl (NF-\u03baBi) to dramatically decrease the growth of ATL cells. Mechanistically, the triple combination exhibited synergistic activity by down-regulating the expression of c-MYC while upregulating the level of the glucocorticoid-induced leucine zipper (GILZ). The triple combination also enhanced apoptosis induction by elevating the expression of active caspase-3 and cleaved PARP. Importantly, the triple combination prolonged the survival of ATL-bearing xenograft mice and inhibited the proliferation of ATL cells from peripheral blood mononuclear cells (PBMCs) of both acute and smoldering\/chronic ATL patients. Therefore, our data provide the rationale for a clinical trial exploring the multiagent combination of BET, PI3K\/AKT, and NF-\u03baB inhibitors for ATL patients and expands the potential treatments for this recalcitrant malignancy.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021005948","type":"journal-article","created":{"date-parts":[[2022,1,14]],"date-time":"2022-01-14T22:04:32Z","timestamp":1642197872000},"page":"2346-2360","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":14,"title":["Triple combination of BET plus PI3K and NF-\u03baB inhibitors exhibit synergistic activity in adult T-cell leukemia\/lymphoma"],"prefix":"10.1182","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6404-7444","authenticated-orcid":false,"given":"Anusara","family":"Daenthanasanmak","sequence":"first","affiliation":[{"name":"Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard N.","family":"Bamford","sequence":"additional","affiliation":[{"name":"Transponics, Essex Junction, VT;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1157-5769","authenticated-orcid":false,"given":"Makoto","family":"Yoshioka","sequence":"additional","affiliation":[{"name":"ConverGene LLC., Cambridge, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyh-Ming","family":"Yang","sequence":"additional","affiliation":[{"name":"Division of Preclinical Innovation, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health, Rockville, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Homan","sequence":"additional","affiliation":[{"name":"CCR-SF Bioinformatics Group and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9604-9762","authenticated-orcid":false,"given":"Baktiar","family":"Karim","sequence":"additional","affiliation":[{"name":"Molecular Histopathology Laboratory, Frederick National Laboratory for Cancer Research (FNLCR), Frederick, MD; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonita R.","family":"Bryant","sequence":"additional","affiliation":[{"name":"Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael N.","family":"Petrus","sequence":"additional","affiliation":[{"name":"Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig J.","family":"Thomas","sequence":"additional","affiliation":[{"name":"Division of Preclinical Innovation, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health, Rockville, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick L.","family":"Green","sequence":"additional","affiliation":[{"name":"Center for Retrovirus Research, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5848-6320","authenticated-orcid":false,"given":"Milos D.","family":"Miljkovic","sequence":"additional","affiliation":[{"name":"Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin C.","family":"Conlon","sequence":"additional","affiliation":[{"name":"Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Waldmann","sequence":"additional","affiliation":[{"name":"Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,4,7]]},"reference":[{"issue":"24","key":"2022040715295263200_B1","first-page":"6977","article-title":"IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2\/IL-2Ralpha interaction","volume":"60","author":"Phillips","year":"2000","journal-title":"Cancer Res."},{"issue":"3","key":"2022040715295263200_B2","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1365-2141.1991.tb08051.x","article-title":"Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87)","volume":"79","author":"Shimoyama","year":"1991","journal-title":"Br J Haematol."},{"issue":"2","key":"2022040715295263200_B3","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s12325-018-0658-4","article-title":"A Review of New Findings in Adult T-cell Leukemia-Lymphoma: A Focus on Current and Emerging Treatment Strategies","volume":"35","author":"Hermine","year":"2018","journal-title":"Adv Ther."},{"issue":"4","key":"2022040715295263200_B4","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1182\/blood.2019004045","article-title":"How I treat adult T-cell leukemia\/lymphoma","volume":"137","author":"Cook","year":"2021","journal-title":"Blood."},{"issue":"7","key":"2022040715295263200_B5","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1182\/blood-2018-02-835991","article-title":"CCR4 mutations associated with superior outcome of adult T-cell leukemia\/lymphoma under mogamulizumab treatment","volume":"132","author":"Sakamoto","year":"2018","journal-title":"Blood."},{"issue":"2","key":"2022040715295263200_B6","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ccell.2018.06.014","article-title":"Targeting the HTLV-I-Regulated BATF3\/IRF4 Transcriptional Network in Adult T Cell Leukemia\/Lymphoma","volume":"34","author":"Nakagawa","year":"2018","journal-title":"Cancer Cell."},{"issue":"2","key":"2022040715295263200_B7","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.cell.2013.03.036","article-title":"Selective inhibition of tumor oncogenes by disruption of super-enhancers","volume":"153","author":"Lov\u00e9n","year":"2013","journal-title":"Cell."},{"issue":"2","key":"2022040715295263200_B8","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.cell.2013.03.035","article-title":"Master transcription factors and mediator establish super-enhancers at key cell identity genes","volume":"153","author":"Whyte","year":"2013","journal-title":"Cell."},{"issue":"7327","key":"2022040715295263200_B9","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nature09504","article-title":"Selective inhibition of BET bromodomains","volume":"468","author":"Filippakopoulos","year":"2010","journal-title":"Nature."},{"issue":"6","key":"2022040715295263200_B10","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","article-title":"BET bromodomain inhibition as a therapeutic strategy to target c-Myc","volume":"146","author":"Delmore","year":"2011","journal-title":"Cell."},{"issue":"8","key":"2022040715295263200_B11","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1093\/annonc\/mdx157","article-title":"BET inhibitors: a novel epigenetic approach","volume":"28","author":"Doroshow","year":"2017","journal-title":"Ann Oncol."},{"issue":"7327","key":"2022040715295263200_B12","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1038\/nature09589","article-title":"Suppression of inflammation by a synthetic histone mimic","volume":"468","author":"Nicodeme","year":"2010","journal-title":"Nature."},{"issue":"2","key":"2022040715295263200_B13","doi-asserted-by":"crossref","first-page":"pkz093","DOI":"10.1093\/jncics\/pkz093","article-title":"Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors","volume":"4","author":"Piha-Paul","year":"2019","journal-title":"JNCI Cancer Spectr."},{"issue":"1","key":"2022040715295263200_B14","doi-asserted-by":"crossref","first-page":"100913","DOI":"10.1016\/j.tranon.2020.100913","article-title":"Enhanced efficacy of JAK1 inhibitor with mTORC1\/C2 targeting in smoldering\/chronic adult T cell leukemia","volume":"14","author":"Daenthanasanmak","year":"2021","journal-title":"Transl Oncol."},{"issue":"2","key":"2022040715295263200_B15","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/nrd4204","article-title":"PI3K and cancer: lessons, challenges and opportunities","volume":"13","author":"Fruman","year":"2014","journal-title":"Nat Rev Drug Discov."},{"issue":"11","key":"2022040715295263200_B16","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1158\/1535-7163.MCT-12-0993-T","article-title":"BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110\u03b1 and p110\u03b4 activities in tumor cell lines and xenograft models","volume":"12","author":"Liu","year":"2013","journal-title":"Mol Cancer Ther."},{"issue":"35","key":"2022040715295263200_B17","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1200\/JCO.2017.75.4648","article-title":"Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma","volume":"35","author":"Dreyling","year":"2017","journal-title":"J Clin Oncol."},{"issue":"18","key":"2022040715295263200_B18","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.1111\/febs.14492","article-title":"NF-\u03baB signaling mechanisms in HTLV-1-induced adult T-cell leukemia\/lymphoma","volume":"285","author":"Harhaj","year":"2018","journal-title":"FEBS J."},{"issue":"5","key":"2022040715295263200_B19","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nri.2017.142","article-title":"NF-\u03baB, inflammation, immunity and cancer: coming of age","volume":"18","author":"Taniguchi","year":"2018","journal-title":"Nat Rev Immunol."},{"issue":"11","key":"2022040715295263200_B20","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1038\/ng.3415","article-title":"Integrated molecular analysis of adult T cell leukemia\/lymphoma","volume":"47","author":"Kataoka","year":"2015","journal-title":"Nat Genet."},{"issue":"12","key":"2022040715295263200_B21","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1158\/1078-0432.CCR-11-2703","article-title":"A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas","volume":"18","author":"Hong","year":"2012","journal-title":"Clin Cancer Res."},{"issue":"6","key":"2022040715295263200_B22","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1182\/blood.V86.6.2350.bloodjournal8662350","article-title":"Tumorigenicity of human T-cell leukemia virus type I-infected cell lines in severe combined immunodeficient mice and characterization of the cells proliferating in\u00a0vivo","volume":"86","author":"Imada","year":"1995","journal-title":"Blood."},{"issue":"9","key":"2022040715295263200_B23","doi-asserted-by":"crossref","first-page":"3788","DOI":"10.1182\/blood-2008-04-154286","article-title":"Human T-cell leukemia virus type-1 antisense-encoded gene, Hbz, promotes T-lymphocyte proliferation","volume":"112","author":"Arnold","year":"2008","journal-title":"Blood."},{"issue":"10","key":"2022040715295263200_B24","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.bmcl.2019.03.014","article-title":"Lead optimization and efficacy evaluation of quinazoline-based BET family inhibitors for potential treatment of cancer and inflammatory diseases","volume":"29","author":"Yang","year":"2019","journal-title":"Bioorg Med Chem Lett."},{"issue":"12","key":"2022040715295263200_B25","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/nbt.3052","article-title":"A community computational challenge to predict the activity of pairs of compounds","volume":"32","author":"Bansal","year":"2014","journal-title":"Nat Biotechnol."},{"issue":"8","key":"2022040715295263200_B26","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1158\/2159-8290.CD-16-1020","article-title":"Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-Small Cell Lung Cancer","volume":"7","author":"Adeegbe","year":"2017","journal-title":"Cancer Discov."},{"issue":"400","key":"2022040715295263200_B27","doi-asserted-by":"crossref","first-page":"eaal1645","DOI":"10.1126\/scitranslmed.aal1645","article-title":"Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition","volume":"9","author":"Yang","year":"2017","journal-title":"Sci Transl Med."},{"issue":"5","key":"2022040715295263200_B28","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1182\/bloodadvances.2019000844","article-title":"Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models","volume":"4","author":"Tarantelli","year":"2020","journal-title":"Blood Adv."},{"issue":"2","key":"2022040715295263200_B29","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res."},{"issue":"9","key":"2022040715295263200_B30","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1182\/blood-2016-09-692574","article-title":"Adult T-cell leukemia: molecular basis for clonal expansion and transformation of HTLV-1-infected T cells","volume":"129","author":"Watanabe","year":"2017","journal-title":"Blood."},{"issue":"7","key":"2022040715295263200_B31","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/sj.leu.2400686","article-title":"Extensive analysis of the retinoblastoma gene in adult T cell leukemia\/lymphoma (ATL)","volume":"11","author":"Hatta","year":"1997","journal-title":"Leukemia."},{"issue":"1","key":"2022040715295263200_B32","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1478-811X-8-31","article-title":"PARP-1 cleavage fragments: signatures of cell-death proteases in neurodegeneration","volume":"8","author":"Chaitanya","year":"2010","journal-title":"Cell Commun Signal."},{"key":"2022040715295263200_B33","doi-asserted-by":"crossref","first-page":"158","DOI":"10.3389\/fphar.2017.00158","article-title":"An Introduction to Terminology and Methodology of Chemical Synergy-Perspectives from Across Disciplines","volume":"8","author":"Roell","year":"2017","journal-title":"Front Pharmacol."},{"issue":"1","key":"2022040715295263200_B34","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41392-018-0008-7","article-title":"Targeting oncogenic Myc as a strategy for cancer treatment","volume":"3","author":"Chen","year":"2018","journal-title":"Signal Transduct Target Ther."},{"issue":"5","key":"2022040715295263200_B35","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/nrm3330","article-title":"The functions and regulation of the PTEN tumour suppressor","volume":"13","author":"Song","year":"2012","journal-title":"Nat Rev Mol Cell Biol."},{"issue":"10","key":"2022040715295263200_B36","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1038\/nm761","article-title":"PKB\/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest","volume":"8","author":"Liang","year":"2002","journal-title":"Nat Med."},{"issue":"20","key":"2022040715295263200_B37","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1093\/jnci\/86.20.1517","article-title":"Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design","volume":"86","author":"Chou","year":"1994","journal-title":"J Natl Cancer Inst."},{"issue":"5","key":"2022040715295263200_B38","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/1074-7613(94)90071-X","article-title":"CTLA-4 can function as a negative regulator of T cell activation","volume":"1","author":"Walunas","year":"1994","journal-title":"Immunity."},{"issue":"20","key":"2022040715295263200_B39","doi-asserted-by":"crossref","first-page":"6180","DOI":"10.1158\/1078-0432.CCR-18-4134","article-title":"Pik3ip1 Is a Negative Immune Regulator that Inhibits Antitumor T-Cell Immunity","volume":"25","author":"Chen","year":"2019","journal-title":"Clin Cancer Res."},{"issue":"3","key":"2022040715295263200_B40","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1182\/blood.V98.3.743","article-title":"Modulation of T-cell activation by the glucocorticoid-induced leucine zipper factor via inhibition of nuclear factor kappaB","volume":"98","author":"Ayroldi","year":"2001","journal-title":"Blood."},{"key":"2022040715295263200_B41","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/B978-0-12-800267-4.00005-5","article-title":"Interleukin 10 receptor signaling: master regulator of intestinal mucosal homeostasis in mice and humans","volume":"122","author":"Shouval","year":"2014","journal-title":"Adv Immunol."},{"issue":"4","key":"2022040715295263200_B42","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1158\/2159-8290.CD-15-0894","article-title":"Targeting CDK4 and CDK6: From Discovery to Therapy","volume":"6","author":"Sherr","year":"2016","journal-title":"Cancer Discov."},{"issue":"9","key":"2022040715295263200_B43","doi-asserted-by":"crossref","first-page":"e603","DOI":"10.1038\/bcj.2017.85","article-title":"Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions","volume":"7","author":"van der Weyden","year":"2017","journal-title":"Blood Cancer J."},{"issue":"13","key":"2022040715295263200_B44","doi-asserted-by":"crossref","first-page":"5218","DOI":"10.1073\/pnas.87.13.5218","article-title":"Transactivation of interleukin 2 and its receptor induces immune activation in human T-cell lymphotropic virus type I-associated myelopathy: pathogenic implications and a rationale for immunotherapy","volume":"87","author":"Tendler","year":"1990","journal-title":"Proc Natl Acad Sci USA."},{"issue":"31","key":"2022040715295263200_B45","doi-asserted-by":"crossref","first-page":"29603","DOI":"10.1074\/jbc.M101522200","article-title":"Inhibition of AP-1 by the glucocorticoid-inducible protein GILZ","volume":"276","author":"Mittelstadt","year":"2001","journal-title":"J Biol Chem."},{"issue":"13","key":"2022040715295263200_B46","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1182\/blood-2004-03-0920","article-title":"Decrease of Bcl-xL and augmentation of thymocyte apoptosis in GILZ overexpressing transgenic mice","volume":"104","author":"Delfino","year":"2004","journal-title":"Blood."},{"issue":"11","key":"2022040715295263200_B47","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/j.1349-7006.2005.00106.x","article-title":"Serum level of soluble CD30 correlates with the aggressiveness of adult T-cell leukemia\/lymphoma","volume":"96","author":"Nishioka","year":"2005","journal-title":"Cancer Sci."},{"issue":"4","key":"2022040715295263200_B48","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/S2352-3026(16)00021-1","article-title":"Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study","volume":"3","author":"Amorim","year":"2016","journal-title":"Lancet Haematol."},{"issue":"26","key":"2022040715295263200_B49","doi-asserted-by":"crossref","first-page":"5948","DOI":"10.1182\/blood-2010-04-277418","article-title":"Autocrine\/paracrine cytokine stimulation of leukemic cell proliferation in smoldering and chronic adult T-cell leukemia","volume":"116","author":"Chen","year":"2010","journal-title":"Blood."},{"issue":"10","key":"2022040715295263200_B50","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1093\/annonc\/mdw282","article-title":"First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin\u2019s lymphomas","volume":"27","author":"Patnaik","year":"2016","journal-title":"Ann Oncol."},{"issue":"1","key":"2022040715295263200_B51","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1186\/s12885-021-08464-6","article-title":"A phase II study of the PI3K inhibitor copanlisib in combination with the anti-CD20 monoclonal antibody rituximab for patients with marginal zone lymphoma: treatment rationale and protocol design of the COUP-1 trial","volume":"21","author":"Grunenberg","year":"2021","journal-title":"BMC Cancer."},{"issue":"6","key":"2022040715295263200_B52","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1007\/s10637-021-01152-z","article-title":"Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and\/or metastatic head and neck squamous cell carcinoma","volume":"39","author":"Marret","year":"2021","journal-title":"Invest New Drugs."},{"issue":"16","key":"2022040715295263200_B53","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1002\/cncr.33590","article-title":"A phase 1 study of the pan-bromodomain and extraterminal inhibitor mivebresib (ABBV-075) alone or in combination with venetoclax in patients with relapsed\/refractory acute myeloid leukemia","volume":"127","author":"Borthakur","year":"2021","journal-title":"Cancer."},{"issue":"22","key":"2022040715295263200_B54","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.1182\/bloodadvances.2021004619","article-title":"Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma","volume":"5","author":"Dickinson","year":"2021","journal-title":"Blood Adv."},{"key":"2022040715295263200_B55","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.blre.2018.11.003","article-title":"The impact of NF-\u03baB signaling on pathogenesis and current treatment strategies in multiple myeloma","volume":"34","author":"Vr\u00e1bel","year":"2019","journal-title":"Blood Rev."},{"issue":"2","key":"2022040715295263200_B56","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s40268-019-0269-9","article-title":"Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later","volume":"19","author":"Robak","year":"2019","journal-title":"Drugs R D."},{"issue":"9","key":"2022040715295263200_B57","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1111\/cas.12735","article-title":"A phase II study of bortezomib in patients with relapsed or refractory aggressive adult T-cell leukemia\/lymphoma","volume":"106","author":"Ishitsuka","year":"2015","journal-title":"Cancer Sci."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/7\/2346\/1887247\/advancesadv2021005948.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/7\/2346\/1887247\/advancesadv2021005948.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T01:16:13Z","timestamp":1674436573000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/7\/2346\/483534\/Triple-combination-of-BET-plus-PI3K-and-NF-B"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,7]]},"references-count":57,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,4,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021005948","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,7]]}}}